_______________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________
Tafinlar + Mekinist is the first and only targeted treatment available for patients with BRAF V600-positive metastatic NSCLC1,2
References
- Tafinlar (dabrafenib) Summary of Product Characteristics
- Mekinist (trametinib) Summary of Product Characteristics.
- Planchard D, et al. Lancet Oncol 2017;18:1307–1316.